1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Blow For Keros’s PAH Candidate As Dreams Of Surpassing Winrevair Fade

 
• By Alexandra Shimmings

The Lexington, MA-based firm lost three quarters of its value after it voluntarily halted dosing in two arms of a Phase II trial of its lead product, cibotercept, on safety concerns. Some observers think the reaction was overblown, however.

Lungs

Keros Therapeutics’ ambitions to go up against Merck & Co’s Winrevair with its investigational pulmonary arterial hypertension therapy, cibotercept, have taken a knock after safety concerns halted enrolment in two treatment arms of its Phase II trial. The move was triggered by unexpected cases of pericardial effusion with the drug at its higher doses, prompting a 73% decline in its share price on NASDAQ on 12 December, and leaving it trading at around cash at $18.43.

Key Takeaways

An unexpected safety concern has halted two arms of a Phase II study of Keros's pulmonary arterial hypertension drug candidate.

Some hope remains...

Keros’s path forward is far from clear, but some analysts say that there is still some hope for the product as well as value in the firm’s wider pipeline, making...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.